Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

NCT03042702 is registered in ClinicalTrials.gov with Innovation Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03042702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03042702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Lead sponsor
Innovation Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 9, 2017
Completion date
November 10, 2017
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer